Evidence map›Paper›PMID 41939876›Full record

ReviewFrontiers in immunology2026

ARG1-polyamine axis: cell-type-specific functions in disease pathogenesis and therapeutic targeting.

Lexing Li, Guoyan Zhu, Mengdie Chen, Bingqing Qiu, Yujia Li, Shiyu Liu, Wei Gu, Leilei Liu

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lexing LiCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.
Guoyan ZhuCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.
Mengdie ChenCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.
Bingqing QiuCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.
Yujia LiCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.
Shiyu LiuCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.
Wei GuDepartment of Biochemistry and Molecular Biology, School of Laboratory Medicine, and Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, China.
Leilei LiuCollege of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ARG1 catalyzes the conversion of L-arginine to L-ornithine, urea, polyamines, and L-proline, thereby balancing nitrogen detoxification with tissue-specific roles in proliferation and immunity. This review delineates the context-dependent functions of ARG1 across diverse cell types-including tumor cells, immune cells, endothelial cells, keratinocytes, and stem cells. In tumors, ARG1 drives immunosuppression and metabolic reprogramming but can paradoxically suppress tumorigenesis. Immune modulation via ARG1-polyamine crosstalk regulates T cell differentiation, macrophage polarization, and microbiota interactions, influencing infection and autoimmunity. Endothelial ARG1 exacerbates obesity-related vascular dysfunction, while keratinocyte ARG1 impacts wound healing and psoriasis. Emerging therapies-such as ARG1 inhibitors, engineered extracellular vesicles, and microbiome interventions-show preclinical promise in cancer, cardiovascular, and neurodegenerative diseases. By mapping ARG1's spatiotemporal metabolic networks, this work highlights its dual roles and positions ARG1 as a central player for precision medicine in complex pathologies.

Indexed as

ArginasePolyaminesAnimalsHumansMetabolic ReprogrammingNeoplasmsARG1 protein, humanArginasePolyaminesARG1immune regulationmetabolic reprogrammingpolyamine metabolismprecision therapy

Identifiers

PMID41939876
PMCPMC13044121

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.